Loading…
Loading…
GMAB does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for GMAB and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for GMAB and 80,000+ other tickers.
See exactly how GMAB's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GMAB and 80,000+ other tickers.
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis…
Company Announcement COPENHAGEN, Denmark; October 23, 2026 Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S ® ) compared to investigator's choice chemotherapy Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC) Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S ® ), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC) , in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab. The trial met its primary endpoint of progression-free survival (PFS), with Rina-S demonstrating a statistically significant and clinically meaningful improvement compared with investigator's choice chemotherapy in the intent-to-treat (ITT) and in the primary analysis set (PAS) populations.
Genmab A/S (NASDAQ: GMAB - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings. Volatility and Risk Genmab A/S has a beta
Company Announcement Net sales of DARZALEX ® in the third quarter of 2026 totaled USD 4,239 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 13, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 4,239 million in the third quarter of 2026. Net trade sales were USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world.
Company Announcement COPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting.At the Extraordinary General Meeting the proposal from the Board of Directors on remuneration of the Board of Directors for 2026, including share-based remuneration in the form of restricted stock units, was approved.
Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Epkinly's efficacy notably exceeds Roche's Polivy in similar settings, positioning GMAB as a potential market leader among T-cell engagers. Frontline DLBCL represents the key growth driver for Epkinly, and I see upside to the company's $3 billion+ peak sales guidance based on better-than-expected treatment effect.